A detailed history of Charles Schwab Investment Management Inc transactions in Greenwich Life Sciences, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 16,455 shares of GLSI stock, worth $229,382. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16,455
Previous 18,454 10.83%
Holding current value
$229,382
Previous $318,000 25.79%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$12.99 - $17.58 $25,967 - $35,142
-1,999 Reduced 10.83%
16,455 $236,000
Q2 2024

Aug 12, 2024

BUY
$12.07 - $19.04 $222,739 - $351,364
18,454 New
18,454 $318,000
Q2 2022

Aug 15, 2022

SELL
$7.14 - $20.36 $72,763 - $207,488
-10,191 Closed
0 $0
Q1 2022

May 13, 2022

BUY
$16.3 - $24.65 $6,063 - $9,169
372 Added 3.79%
10,191 $200,000
Q2 2021

Aug 16, 2021

BUY
$31.24 - $53.6 $306,745 - $526,298
9,819 New
9,819 $442,000

Others Institutions Holding GLSI

About Greenwich LifeSciences, Inc.


  • Ticker GLSI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 12,848,200
  • Market Cap $179M
  • Description
  • Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who ha...
More about GLSI
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.